Linked Life Data

21506195

Source:http://linkedlifedata.com/resource/pubmed/id/21506195

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2011-5-24
pubmed:abstractText
Morbidity and mortality have declined only modestly in patients with clinical acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), despite extensive research into the pathophysiology. Current treatment remains primarily supportive with lung-protective ventilation and a fluid conservative strategy. Pharmacologic therapies that reduce the severity of lung injury in preclinical models have not yet been translated to effective clinical treatment options. Consequently, further research in translational therapies is needed. Cell-based therapy with mesenchymal stem cells (MSCs) is one attractive new therapeutic approach. MSCs have the capacity to secrete multiple paracrine factors that can regulate endothelial and epithelial permeability, decrease inflammation, enhance tissue repair, and inhibit bacterial growth. This review will focus on recent studies, which support the potential therapeutic use of MSCs in ALI/ARDS, with an emphasis on the role of paracrine soluble factors.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1549-4918
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 AlphaMed Press.
pubmed:issnType
Electronic
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
913-9
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors.
pubmed:affiliation
Department of Anesthesiology, University of California San Francisco, California 94143, USA. leejw@anesthesia.ucsf
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Extramural